MedTrace Logo

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

NCT00320749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-06-27

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants. In addition, researchers will assess data about preliminary efficacy in patients with this treatment approach.

Conditions

Interventions

DRUG

Capecitabine

Will be give on days 8-21

DRUG

Docetaxel

Will be given on days 1 and 8,

DRUG

Gemcitabine

A fixed dose rate will be give on days 8 and 15.

Sponsors & Collaborators

  • University of Michigan Rogel Cancer Center

    collaborator OTHER

  • Tony Bekaii-Saab

    lead OTHER

Principal Investigators

  • Tanios Saab · Ohio State University

  • Tanios Saab, M.D. · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-10-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320749 on ClinicalTrials.gov